Cargando…

Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the fifth most common cancer in men worldwide and the second leading cause of cancer death. Liver transplantation (LT) is one of the treatment options for patients with HCC. Recently, there have been many reports of the usefulness of locoregional the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogawa, Kohei, Takada, Yasutsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773674/
https://www.ncbi.nlm.nih.gov/pubmed/35053558
http://dx.doi.org/10.3390/cancers14020396
_version_ 1784636152016273408
author Ogawa, Kohei
Takada, Yasutsugu
author_facet Ogawa, Kohei
Takada, Yasutsugu
author_sort Ogawa, Kohei
collection PubMed
description SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the fifth most common cancer in men worldwide and the second leading cause of cancer death. Liver transplantation (LT) is one of the treatment options for patients with HCC. Recently, there have been many reports of the usefulness of locoregional therapy, such as transarterial chemoembolization and radiofrequency ablation, for HCC as pretreatment before LT. In Western countries, locoregional therapy is used to bridge until transplantation to prevent drop-outs from the waiting list or for downstaging to treat patients with advanced HCC who initially exceed the criteria for LT. With the progress of locoregional therapy, new reports on the effects of bridging and downstaging locoregional therapy as pretransplant treatment are increasing in number. ABSTRACT: Recently, there have been many reports of the usefulness of locoregional therapy such as transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma (HCC) as pretreatment before liver transplantation (LT). Locoregional therapy is performed with curative intent in Japan, where living donor LT constitutes the majority of LT due to the critical shortage of deceased donors. However, in Western countries, where deceased donor LT is the main procedure, LT is indicated for early-stage HCC regardless of liver functional reserve, and locoregional therapy is used for bridging until transplantation to prevent drop-outs from the waiting list or for downstaging to treat patients with advanced HCC who initially exceed the criteria for LT. There are many reports of the effect of bridging and downstaging locoregional therapy before LT, and its indications and efficacy are becoming clear. Responses to locoregional therapy, such as changes in tumor markers, the avidity of FDG-PET, etc., are considered useful for successful bridging and downstaging. In this review, the effects of bridging and downstaging locoregional therapy as a pretransplant treatment on the results of transplantation are clarified, focusing on recent reports.
format Online
Article
Text
id pubmed-8773674
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87736742022-01-21 Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation Ogawa, Kohei Takada, Yasutsugu Cancers (Basel) Review SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the fifth most common cancer in men worldwide and the second leading cause of cancer death. Liver transplantation (LT) is one of the treatment options for patients with HCC. Recently, there have been many reports of the usefulness of locoregional therapy, such as transarterial chemoembolization and radiofrequency ablation, for HCC as pretreatment before LT. In Western countries, locoregional therapy is used to bridge until transplantation to prevent drop-outs from the waiting list or for downstaging to treat patients with advanced HCC who initially exceed the criteria for LT. With the progress of locoregional therapy, new reports on the effects of bridging and downstaging locoregional therapy as pretransplant treatment are increasing in number. ABSTRACT: Recently, there have been many reports of the usefulness of locoregional therapy such as transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma (HCC) as pretreatment before liver transplantation (LT). Locoregional therapy is performed with curative intent in Japan, where living donor LT constitutes the majority of LT due to the critical shortage of deceased donors. However, in Western countries, where deceased donor LT is the main procedure, LT is indicated for early-stage HCC regardless of liver functional reserve, and locoregional therapy is used for bridging until transplantation to prevent drop-outs from the waiting list or for downstaging to treat patients with advanced HCC who initially exceed the criteria for LT. There are many reports of the effect of bridging and downstaging locoregional therapy before LT, and its indications and efficacy are becoming clear. Responses to locoregional therapy, such as changes in tumor markers, the avidity of FDG-PET, etc., are considered useful for successful bridging and downstaging. In this review, the effects of bridging and downstaging locoregional therapy as a pretransplant treatment on the results of transplantation are clarified, focusing on recent reports. MDPI 2022-01-13 /pmc/articles/PMC8773674/ /pubmed/35053558 http://dx.doi.org/10.3390/cancers14020396 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ogawa, Kohei
Takada, Yasutsugu
Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation
title Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation
title_full Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation
title_fullStr Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation
title_full_unstemmed Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation
title_short Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation
title_sort role of pretransplant treatments for patients with hepatocellular carcinoma waiting for liver transplantation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773674/
https://www.ncbi.nlm.nih.gov/pubmed/35053558
http://dx.doi.org/10.3390/cancers14020396
work_keys_str_mv AT ogawakohei roleofpretransplanttreatmentsforpatientswithhepatocellularcarcinomawaitingforlivertransplantation
AT takadayasutsugu roleofpretransplanttreatmentsforpatientswithhepatocellularcarcinomawaitingforlivertransplantation